



For Immediate Release

Technomark Life Sciences Pursues Co-Development With Biotechnology and Other Life Science Companies

DURHAM (NC-USA)/ LONDON (UK), February 27, 2009

Technomark Life Sciences, a 20 year old life science group, announced today that it is pursuing co-development opportunities with life science companies. The Company will work with biotechnology and other life science companies on a risk sharing basis to progress product development.

"We are very excited to be in a position now to partner with biotechnology and other life science companies on their preclinical or clinical product development," said Allen Hakimi, Managing Director of Technomark. The Company will invest using product development services as capital in order to share and reduce the cost of the development program, in exchange for equity, downstream royalties, and/or regional rights in emerging countries such as India, China, and South Africa.

Technomark hopes to identify at least five development programs on which it can participate in 2009. While being quite flexible on its investment criteria – biologic and chemical entity drug candidates, medical device, and diagnostics -- co-investing with institutional investors or having a Board seat will not be a pre-requisite.

For more information, please contact:

Allen Hakimi
Managing Director
Technomark Life Sciences
+1 919 656 3624
+44 (0) 751 323 8920
ahakimi@technomarkls.com

###

About TECHNOMARK

Technomark Life Sciences is a specialty life science firm with a world-wide reputation for excellence. With offices in Research Triangle Park (NC-USA), London (UK), Mumbai (India), and Nanjing (China), the Company specializes in product development, regional licensing and partnering, and CRO/CMO corporate growth. For more information please visit www.technomarkls.com.